Cac Scoring Indication Interpretation 2026

---
name: cac-scoring-indication-interpretation-2026
description: Decide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clinician asks should I order a CAC score, CAC indications, what does CAC 150 mean, treatment goals with CAC score, repeat CAC frequency, CAC in a smoker, CAC vs CCTA, is CAC useful in intermediate risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
---

# Coronary Artery Calcium Scoring — Indication, Interpretation & LLT Modification (2026)

Use CAC scoring to reclassify primary-prevention patients when the PREVENT-ASCVD score leaves clinical uncertainty. CAC results then **modify LDL and non-HDL treatment goals**, not just the decision to treat.

---

## Step 1 — Confirm the patient is a CAC candidate

**Class 1 indication:**

- **Men ≥40 years OR women ≥45 years**
- **Borderline (3–<5%) OR intermediate (5–<10%)** 10-year PREVENT-ASCVD risk
- **Clinical uncertainty** about whether to initiate lipid-lowering therapy
- No existing ASCVD, no automatic Class-1 LLT indication (otherwise CAC does not change the "whether" decision)

**CAC has no clear role in:**

- **High (≥10%) 10-year ASCVD risk** — proceed to high-intensity statin regardless; CAC should not be used to defer LLT in this group
- **Low (<3%) 10-year risk WITHOUT other high-risk features** — CAC rarely changes management
- **Severe hypercholesterolaemia (LDL ≥190 mg/dL)** or clinical/genetic FH — treat regardless; CAC may still inform intensity but not initiation
- **Diabetes with multiple ASCVD risk factors** or long-standing poorly-controlled DM — automatic high-intensity statin
- **Patients <40 years (men) or <45 years (women)** — CAC yield is low; the test under-identifies early non-calcified plaque

---

## Step 2 — Order the CAC scan

- **Non-contrast, gated chest CT** of the heart
- Low radiation dose (~1 mSv, lower than mammography)
- Results reported in **Agatston Units (AU)** AND **age/sex-matched percentile**
- No fasting, no contrast, no beta-blockade needed in most centres

**Consider patient-level issues before ordering:**

- **Incidental findings** on the scan (lung nodules, aortic dilation) may prompt further tests — brief the patient
- **Radiation** is small but not zero; avoid routine repeated scans more often than every 3–7 years
- **Cost / insurance coverage** varies widely
- **Patient anxiety** about either a positive or a zero result — set expectations in advance

---

## Step 3 — Interpret the CAC score and modify LDL / non-HDL goals

| CAC score (Agatston Units) | Risk reclassification | LDL-C goal | Non-HDL-C goal | Statin |
|---|---|---|---|---|
| **0 AU** (with no other high-risk features) | **Low** — can **defer LLT**; repeat CAC in **3–7 years** | — | — | Lifestyle |
| **0 AU with FH / LDL ≥190 / DM / age >40 + smoker / strong family history premature ASCVD** | Treat regardless (CAC = 0 is NOT reassuring in these groups) | Per baseline risk / FH criteria | Per baseline risk | Moderate-to-high |
| **1–99 AU** OR **<75th percentile** | **Reclassify toward LLT** (Class 2a) | **<100 mg/dL** (≥30% reduction) | **<130 mg/dL** | Moderate-intensity |
| **100–299 AU** OR **≥75th percentile** OR **moderate-to-severe incidental CAC on non-cardiac CT** | **Reclassify toward LLT** (Class 1) | **<70 mg/dL** (≥50% reduction) | **<100 mg/dL** | Moderate-to-high |
| **≥300 AU** | **High-risk** — treat as such | **<70 mg/dL** (≥50% reduction) | **<100 mg/dL** | High-intensity |
| **≥1000 AU** | **Very-high-risk** — aggressive goals (Class 1) | **<55 mg/dL** | **<85 mg/dL** | High-intensity + consider non-statin add-on |

**ApoB goals once LDL-C and non-HDL-C targets are met** (Class 2 for ApoB measurement in LLT recipients with diabetes / CKM syndrome / TG ≥200):

| LDL-C goal | ApoB goal |
|---|---|
| <100 mg/dL | <90 mg/dL |
| <70 mg/dL | <70 mg/dL |
| <55 mg/dL | <55 mg/dL |

---

## Step 4 — Decide repeat CAC timing

- **CAC = 0 and deferring LLT** → repeat in **3–7 years** to detect calcium development
- **CAC >0 and on LLT** → routine repeat CAC is NOT recommended; statins stabilise plaque but may paradoxically increase calcium density. Serial CAC on-statin is not a treatment-monitoring tool
- **Progression of CAC** is itself a risk signal if measured, but monitoring with repeat CAC in treated patients is not current standard

---

## Step 5 — Use CAC thoughtfully in special scenarios

### Incidental CAC on a non-cardiac CT (e.g. chest CT for other indications)

- A **non-gated chest CT** showing CAC is a legitimate signal
- Qualitative grading (none / mild / moderate / severe) is clinically useful
- **Moderate-to-severe incidental CAC → treat as CAC 100–299 or ≥300** per the above table
- **Absence of CAC on a non-gated scan does NOT equate to a CAC score of 0** (high false-negative rate due to non-gated acquisition) — do a dedicated CAC scan if the "zero" needs to be clinically relied on

### CT coronary angiography (CCTA)

- Class **2b** recommendation to inform risk assessment in individuals with high burden of **non-calcified plaque** (patients with HIV, inflammatory disorders, diabetes)
- Not a first-line tool for routine primary prevention risk assessment
- Guideline does NOT address downstream ischaemic testing based on CAC
- **The National Lipid Association specifically recommends AGAINST** using CAC alone to test for obstructive CAD or ischaemia

### Smokers

- Current cigarette smoking changes the calculus — CAC = 0 in a smoker is less reassuring than in a non-smoker; shared decision still leans toward LLT

---

## Guardrails

- **CAC = 0 is reassuring but NOT a license to ignore risk** — repeat in 3–7 years, and treat regardless if FH / LDL ≥190 / DM / strong family history / smoker
- **CAC in a high-risk patient does not help the decision** — do not use CAC to try to DE-escalate treatment in a patient already classified as high-risk by PREVENT or by automatic Class-1 criteria
- **Incidental non-gated CAC underestimates true CAC** — a "no CAC" report from a non-gated CT is not equivalent to a formal CAC = 0 scan
- **CAC does not test for ischaemia** — a high CAC does not mandate stress testing; a low CAC does not exclude an acute coronary event
- **Do NOT repeat CAC yearly or every 2 years** — biologically CAC changes slowly in treated patients and repeated radiation adds up over a lifetime
- **ApoB goals should drive final intensification** in patients with diabetes, CKM syndrome, or TG ≥200 even after LDL-C and non-HDL-C targets are met
- **Discuss cost and incidental findings** before ordering — a positive scan may lead to downstream testing the patient is not expecting
- **CAC = 0 under age 40 is uninformative** — early plaque is often non-calcified; waiting until the Class-1 age window (men ≥40, women ≥45) improves yield
- **Do not use CAC to replace a conversation** — it is a reclassification tool, not a decision-making substitute

---

## Related MD2SKILL skills

- `prevent-ascvd-risk-calculator-interpretation` — the Step-1 risk calculation that defines the CAC indication
- `dyslipidemia-cpr-framework-2026` — the full CPR framework (CAC is the "R" step)
- `dyslipidemia-ldl-treatment-goals-2026` — the LDL and non-HDL goals that CAC modifies

---

## Sources

**Primary:** 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Multisociety Guideline on the Management of Dyslipidaemia.

**Review used for extraction:** Abramov D et al. **Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.** *Current Atherosclerosis Reports.* 2026;28:63. DOI: 10.1007/s11883-026-01437-9. Section "Key Message 5: Additional Risk Stratification — Coronary Artery Calcium" and Table 1.